Fundz
Real-time · AI · Cross-signal

POXEL SA just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on POXEL SA, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Poxel to receive payment and royalties from Sumitomo Pharma for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

Jan 20, 2025•over 1 year ago

Contract Type

agreement

LyonBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Poxel, a clinical stage biopharmaceutical company, is set to receive positive net royalties and a sales-based payment from Sumitomo Pharma as the net sales of TWYMEEG® in Japan reached JPY 5 billion in Sumitomo Pharma's fiscal year 2024. These funds will be used to repay the bonds issued to OrbiMed, according to the agreement signed between Poxel and OrbiMed in September 2024.

Company Information

Company

POXEL SA

Location

Lyon, Auvergne Rhône Alpes, France

About

Poxel is a dynamic clinical-stage biopharmaceutical company focused on developing innovative treatments for chronic severe metabolic diseases, including metabolic-associated steatohepatitis (MASH) and rare metabolic disorders. The company's products are aimed at providing new therapies for type 2 diabetes and potentially expanding treatment options for affected patients. Poxel aims to leverage its expertise to bring significant advancements in the field of metabolic diseases.

Predictive Intelligence
Strategic

ML-powered predictions for POXEL SA's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months